Shots: The P-III KEYNOTE-355 (part 1 & 2) study involves assessing of Keytruda (200mg, IV, on day 1 of each 21-day cycle) + CT vs PBO + CT in 30 […]readmore
Shots: The P-III PROSPER study involves assessing of Xtandi (160mg, QD) + ADT vs PBO + ADT in 1400 patients with nmCRPC across the US, EU, SA, Canada, and the […]readmore